摘要
Intertriginous and facial involvement are manifestations of psoriasis that require a different approach than is used for typical plaque psoriasis on other skin areas. Topical corticosteroids are the primary treatment for psoriasis; however, the side effects of corticosteroids are magnified on intertriginous and facial skin. Topical tacrolimus offers the potential for anti-inflammatory effect without the atrophy or other local side effects associated with the use of topical corticosteroids. To determine the efficacy and tolerability of 0.1%tacrolimus ointment for the treatment of facial or intertriginous psoriasis. One hundred sixty-seven patients 16 years or older were evaluated in an 8-week, randomized, double-blind, vehicle-controlled, multi-center study. Uponentryintothestudy,patientswererandomized2:1toapply the tacrolimus ointment 0.1%or vehicle twice daily to all psoriatic lesions of the face or intertriginous areas for 8 weeks. The physician’s global assessment was used to assess improvement from baseline. The inverse psoriasis severity for patients was measured using a 6-point scale from clear to very severe. As early as day 8, more patients (P=. 004) had cleared or achieved excellent improvement in the 0.1%tacrolimus ointment group compared to the vehicle group (24.8%vs 5.8%). At the end of the 8-week treatment period 65.2%of the tacrolimus ointment group and 31.5%of the vehicle were clear or almost clear (P < .0001) based on a Static Severity Score. Adverse events were similar in the 0.1%tacrolimus ointment and vehicle groups. Tacrolimus ointment is an effective treatment for psoriasis of the face or intertriginous areas.
Intertriginous and facial involvement are manifestations of psoriasis that require a different approach than is used for typical plaque psoriasis on other skin areas. Topical corticosteroids are the primary treatment for psoriasis; however, the side effects of corticosteroids are magnified on intertriginous and facial skin. Topical tacrolimus offers the potential for anti-inflammatory effect without the atrophy or other local side effects associated with the use of topical corticosteroids. To determine the efficacy and tolerability of 0.1%tacrolimus ointment for the treatment of facial or intertriginous psoriasis. One hundred sixty-seven patients 16 years or older were evaluated in an 8-week, randomized, double-blind, vehicle-controlled, multi-center study. Uponentryintothestudy,patientswererandomized2:1toapply the tacrolimus ointment 0.1%or vehicle twice daily to all psoriatic lesions of the face or intertriginous areas for 8 weeks. The physician’s global assessment was used to assess improvement from baseline. The inverse psoriasis severity for patients was measured using a 6-point scale from clear to very severe. As early as day 8, more patients (P=. 004) had cleared or achieved excellent improvement in the 0.1%tacrolimus ointment group compared to the vehicle group (24.8%vs 5.8%). At the end of the 8-week treatment period 65.2%of the tacrolimus ointment group and 31.5%of the vehicle were clear or almost clear (P < .0001) based on a Static Severity Score. Adverse events were similar in the 0.1%tacrolimus ointment and vehicle groups. Tacrolimus ointment is an effective treatment for psoriasis of the face or intertriginous areas.
